10x Genomics
273 hedge funds and large institutions have $1.5B invested in 10x Genomics in 2024 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 89 increasing their positions, 92 reducing their positions, and 49 closing their positions.
27% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 49
3% more funds holding
Funds holding: 266 → 273 (+7)
0.32% less ownership
Funds ownership: 98.1% → 97.78% (-0.32%)
3% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 92
31% less call options, than puts
Call options by funds: $1.4M | Put options by funds: $2.02M
36% less capital invested
Capital invested by funds: $2.36B → $1.5B (-$853M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$51.8M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$28.9M |
| 3 |
D.E. Shaw & Co
New York
|
+$19.2M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$18.8M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$48.8M |
| 2 |
Morgan Stanley
New York
|
-$40.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.8M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$21.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.2M |
TXG Hedge Fund Activity: Q4 2024 in Review
273 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2024, worth a combined $1.5B — down 36% from $2.36B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new TXG positions and 49 closed out — a net gain of 13 holders — while 89 added to existing stakes and 92 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $51.8M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $48.8M sold.
- 273 institutional investors held 10x Genomics (TXG) as of Q4 2024, up from 266 in Q3 2024.
- Funds reported $1.5B of 10x Genomics stock for Q4 2024, down 36% quarter-over-quarter.
- 62 funds opened new 10x Genomics positions in Q4 2024 and 49 closed out, a net change of +13 holders.
- The largest 10x Genomics buyer in Q4 2024 was RA Capital Management, an estimated $51.8M added.
- The largest 10x Genomics seller in Q4 2024 was T. Rowe Price Investment Management, an estimated $48.8M sold.
Based on aggregated 13F filings for Q4 2024.